Inactive Instrument

BioRestorative Therapies, Inc. Stock price Other OTC

Equities

BRTX

US0906554086

Biotechnology & Medical Research

Sales 2023 * 142K Sales 2024 * 60K Capitalization 9.13M
Net income 2023 * -14M Net income 2024 * -17M EV / Sales 2023 * 64.3 x
Net cash position 2023 * - Net cash position 2024 * - EV / Sales 2024 * 152 x
P/E ratio 2023 *
-0.4 x
P/E ratio 2024 *
-0.64 x
Employees -
Yield 2023 *
-
Yield 2024 *
-
Free-Float 80.53%
More Fundamentals * Assessed data
Dynamic Chart
Managers TitleAgeSince
Chief Executive Officer 53 18-09-30
Director of Finance/CFO - 21-11-03
Compliance Officer - -
Members of the board TitleAgeSince
Director/Board Member 51 21-10-28
Director/Board Member 59 21-10-28
Chief Tech/Sci/R&D Officer 49 11-04-12
More insiders
BioRestorative Therapies, Inc. is a clinical-stage company engaged in developing therapeutic products, using cell and tissue protocols, primarily involving adult stem cells. The Company has two core programs that relate to the treatment of disc/spine disease and metabolic disorders. Its lead cell therapy candidate, BRTX-100, is a product formulated from autologous (or a person's own) cultured mesenchymal stem cells (MSCs), collected from the patient's bone marrow. BRTX-100 is used for the non-surgical treatment of painful lumbosacral disc disorders or as a complimentary therapeutic to a surgical procedure. The Company is engaged in developing a cell-based therapy candidate, ThermoStem Program, which targets obesity and metabolic disorders using brown adipose (fat)-derived stem cells (BADSC) to generate brown adipose tissue (BAT). It has also licensed an investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs.
More about the company
  1. Stock
  2. Equities
  3. Stock BioRestorative Therapies, Inc.
  4. Stock BioRestorative Therapies, Inc. - Other OTC